External validation of the Ferguson pulmonary risk score for predicting major pulmonary complications after oesophagectomy
|
|
- Wilfrid Parker
- 5 years ago
- Views:
Transcription
1 European Journal of Cardio-Thoracic Surgery 49 (2016) doi: /ejcts/ezv021 Advance Access publication 26 February 2015 ORIGINAL ARTICLE Cite this article as: Reinersman JM, Allen MS, Deschamps C, Ferguson MK, Nichols FC, Shen KR et al. External validation of the Ferguson pulmonary risk score for predicting major pulmonary complications after oesophagectomy. Eur J Cardiothorac Surg 2016;49: a External validation of the Ferguson pulmonary risk score for predicting major pulmonary complications after oesophagectomy J. Matthew Reinersman a, Mark S. Allen a, Claude Deschamps a, Mark K. Ferguson b, Francis C. Nichols a, K. Robert Shen a, Dennis A. Wigle a and Stephen D. Cassivi a, * Division of General Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA b Department of Surgery, The University of Chicago, Chicago, IL, USA * Corresponding author. Division of General Thoracic Surgery, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Tel: ; fax: ; cassivi.stephen@mayo.edu (S.D. Cassivi). Received 13 September 2014; received in revised form 23 December 2014; accepted 2 January 2015 Abstract OBJECTIVES: Pulmonary complications remain a frequent cause of morbidity in patients undergoing oesophagectomy. Risk screening tools assist in patient stratification. Ferguson proposed a risk score system to predict major pulmonary complications after oesophagectomy. Our objective was to externally validate this risk score system. METHODS: We analysed our institutional database for patients undergoing oesophagectomy for cancer from August 2009 to December We analysed patients who had complete documentation of variables used in the Ferguson risk score calculation: forced expiratory volume in the 1 s, diffusion capacity of the lung for carbon monoxide, performance status and age. One hundred and thirty-six patients qualified for analysis in the validation study. Outcome variables measured included major pulmonary complications, defined as need for reintubation for respiratory failure and pneumonia. The risk score was then calculated for each individual based on the model. Incidence of major pulmonary events was assessed in the five risk class groupings to assess the discriminative ability of the Ferguson score. RESULTS: Major pulmonary complications occurred in 35% of patients (47/136). Overall mortality was 6% (8/136). Patients were grouped into five risk categories according to their Ferguson pulmonary risk score: 0 2, 8 patients (6%); 3 4, 24 patients (18%); 5 6, 49 patients (36%); 29 patients (21%); 9 14, 26 patients (19%). The incidence of major pulmonary complications in these categories was 0, 17, 20, 41 and 77%, respectively. The accuracy of the risk score system for predicting major pulmonary complications was 76% (P < ). CONCLUSIONS: This pulmonary risk scoring system is a reliable instrument to be used during the preoperative phase to differentiate patients who may be at higher risk for pulmonary complications after oesophagectomy. These data can assist in patient selection, and in patient education/informed consent and can guide postoperative management. Keywords: Oesophageal neoplasms Oesophagectomy Patient selection Outcomes Pneumonia Respiratory insufficiency INTRODUCTION Oesophageal cancer is the sixth leading cause of cancer-related mortality worldwide, and has the fastest growing incidence of any cancer in the USA [1]. Surgical resection is the mainstay of therapy, offering a chance of long-term survival. Oesophagectomy is associated with risk, in both short-term complications and longer term loss of quality of life. Over half of the patients suffer at least one adverse postoperative event [2]. Surgeons have a need for methods to better predict risk for these patients. Risk stratification is a valuable tool to preoperatively identify which patients are at increased risk. An addition to risk stratification is the advent of risk scoring systems. These allow each patient to be stratified into a Presented at the 28th Annual Meeting of the European Association for Cardio- Thoracic Surgery, Milan, Italy, October predictive group based on the system. This technique provides an estimate of an individual s actual risk. Pulmonary complications remain a frequent postoperative event after oesophagectomy, significantly contributing to prolonged length of stay and postoperative mortality. Ferguson et al. [3] developed a risk scoring system to predict postoperative pulmonary complication following oesophagectomy. These data were collected from their institutional database over 30 years. Utilizing these data, they created a score system using four factors: age, performance status, forced expiratory volume in the first second expressed as percent predicted (FEV1%) and diffusion capacity of the lung for carbon monoxide expressed as percent predicted (DLCO%). Using weighted scores of these four variables, the scoring system predicted pulmonary complications with an accuracy of 70.8%. Our aim was to externally validate the risk score s accuracy using our institutional data. THORACIC The Author Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
2 334 J.M. Reinersman et al. / European Journal of Cardio-Thoracic Surgery MATERIALS AND METHODS The study was reviewed, and approved by our Institutional Review Board. Specific patient consent for this study was waived. We performed a retrospective analysis of our prospectively collected patient database for patients undergoing oesophagectomy for cancer from August 2009 to December We collected variables necessary to calculate the Ferguson pulmonary risk score: age, performance status, FEV1 and DLCO%. Pulmonary function tests utilized for this study were obtained prior to resection but after neoadjuvant therapy, if administered. We identified 136 patients that qualified for analysis in the validation study. Two-hundred and seven patients were excluded during the inclusion period secondary to insufficient variables to calculate the risk score. We then analysed the presence of outcome variables. Major outcome variables were major pulmonary complications, defined as need for reintubation for isolated respiratory insufficiency and/or pneumonia, documented by fever, elevated white blood cell count and pulmonary infiltrate requiring antibiotic therapy. Other outcomes evaluated were mortality, defined as 30-day operative or in-hospital mortality. Oesophagectomy was partial or total, and performed utilizing the following approaches: Ivor Lewis, transhiatal, McKeown modification of the Ivor Lewis approach, total or hybrid minimally invasive approaches or resection without reconstruction. Patients were managed according to our standard institution protocol with epidural catheters for pain management, early extubation and ambulation and early enteral nutrition via jejunostomy tube (Supplemental material). The statistical analysis was conducted using SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA). For univariate comparisons, chi-square tests were utilized to evaluate the association between categorical variables and occurrence of pulmonary complication; when expected counts were low, Fisher s exact test was used. The association between continuous variables and pulmonary complications was analysed using t-tests and Wilcoxon rank-sum tests. The Ferguson pulmonary risk score is a 5-level risk score comprising four weighted factors (age, performance status, FEV1% and DLCO%), each having 5 different score categories from 0 to 4 (Table 1) [3]. According to the individual weighted scores assigned to each factor, an aggregate score was calculated for each patient. Patients were then grouped into the five different categories of risk according to their scores, and incidence of major pulmonary events was assessed in each class. Table 1: Ferguson weighted scoring system for pulmonary complications Assigned score value Age < >80 Performance Status (Zubrod/ECOG) FEV1% <70 DLCO% <70 ECOG: eastern cooperative oncology group; FEV1%: forced expiratory volume in the first second expressed as percent predicted; DLCO%: diffusion capacity of the lung for carbon monoxide expressed as percent predicted. The risk score was calculated for each individual based on the model. The incidence of major pulmonary events was assessed in the five risk class groupings to assess the discriminative ability of the pulmonary risk score. Receiver operating characteristic curve analysis was utilized to evaluate the accuracy of the system to predict pulmonary complications. As a method of directly validating the scoring system, comparison between the expected and observed outcomes was performed using the Hosmer Lemeshow goodness-of-fit test. RESULTS During the study period, 136 patients undergoing oesophagectomy had the necessary variables available for calculation of the Ferguson risk score. A risk score was not able to be calculated in another 207 patients during this same time period, due to missing pulmonary function tests. Neoadjuvant chemoradiotherapy was given to 81% (110/136) of patients. The majority of resections were for tumours of the lower third (66/136; 49%) or gastroesophageal junction (62/136; 46%) and the histology was adenocarcinoma in 87% (118/136). Approaches to oesophagectomy included the following: Ivor Lewis in 96 (71%), transhiatal in 21 (15%), minimally invasive in 9 (7%), McKeown in 8 (6%) and resection without reconstruction in 2 (2%). Operative mortality occurred in 8 patients (6%). Major morbidity occurred in 42% (57/136). These included anastomotic leak in 13% of patients (18/136), pulmonary complications in 47 patients (35%), reoperation in 17% (23/136), empyema in 7% (9/136), chylothorax 6% (8/136), myocardial infarction 2% (2/136) and pulmonary embolus 2% (3/136). Major pulmonary events were pneumonia in 44 patients and isolated respiratory failure requiring intubation in 3 additional patients. Of the pneumonia patients, over half (23; 52%) required reintubation, and 48% (21/44) required bronchoscopy for secretion management. Univariate analysis of the cohort for pulmonary complications is detailed in Table 2. The following were found to be significant predictors: Zubrod/Eastern Cooperative Oncology Group (ECOG) performance status 2 or 3, American Society of Anesthesiology (ASA) classification III, congestive heart failure, hypertension, peripheral vascular disease, smoking status, chronic obstructive pulmonary disease (COPD), insulin requiring diabetes (DM) and worsening FEV1 and DLCO. Patients suffering a major pulmonary complication had an increased rate of mortality at 15% (7/47) compared with those who did not suffer one (mortality 1%; 1/89) (P < 0.001). Seven of the 8 patients who died suffered major pulmonary complications, whereas the rate of major pulmonary complications in the rest of the cohort was 31% (40/128). Overall median length of stay for the entire cohort was 8 days [interquartile range (IQR): 7 13 days]. Median length of stay was significantly longer for patients with pulmonary complications at 12 days (IQR: 8 23 days) compared with those without pulmonary complications, 7 days (IQR: 6 10 days) (P < 0.001). Figure 1 displays the distribution of patients according to their pulmonary risk score, and Fig. 2 graphically illustrates the incidence of pulmonary complications according to risk score. The patients were then subdivided into the five risk categories based on the score number: 0 2, 3 4, 5 6, 7 8and 9 13, as divided in the Ferguson pulmonary risk scoring system. The rate of major pulmonary complications in these patients according to the risk categories was then determined, and displayed in Table 3 (P < 0.001) and detailed graphically in Fig. 3.
3 J.M. Reinersman et al. / European Journal of Cardio-Thoracic Surgery 335 Table 2: Characteristics and univariate analysis of patients undergoing oesophagectomy Characteristics All patients Pulmonary complication (no) Pulmonary complication (yes) P-value Age 63.8 (±8.5) 63.1 (±8.7) 65.2 (± 8.1) 0.18 Gender 0.95 Male 119 (87%) 78 (65%) 41 (35%) Female 17 (13%) 11 (65%) 6 (35%) Performance status (Zubrod/ECOG) < (70%) 38 (30%) (0%) 9 (100%) ASA classification I/II (85%) 6 (15%) III (57%) 41 (43%) Weight loss 3 months (kg) 4.9 (±5.4) 4.5 (±4.9) 5.8 (±6) 0.16 Congestive heart failure No (67%) 43 (33%) Yes 5 1 (20%) 4 (80%) Coronary artery disease 0.36 No (67%) 36 (33%) Yes (58%) 11 (42%) Peripheral vascular disease No (70%) 38 (30%) Yes 11 2 (18%) 9 (82%) Hypertension No (76%) 14 (24%) Yes (58%) 33 (42%) COPD No (71%) 31 (29%) Yes (45%) 16 (55%) Preoperative chemoradiotherapy 0.36 No (58%) 11 (42%) Yes (67%) 36 (33%) Steroids 1.00 No (65%) 46 (35%) Yes 3 2 (67%) 1 (33%) Prior cardiothoracic surgery 0.34 No (67%) 37 (33%) Yes (56%) 10 (44%) Diabetes mellitus 0.23 No (68%) 32 (32%) Yes (57%) 15 (43) Diabetic category No DM (68%) 32 (32%) Non-insulin (69%) 8 (31%) Insulin 9 2 (22%) 7 (78%) Cigarette smoking Never (82%) 6 (18%) Past smoker (63%) 31 (37%) Current (50%) 10 (50%) FEV1% predicted % (70%) 37 (30%) <60% 13 3 (23%) 10 (77%) DLCO % predicted % (69%) 38 (31%) <60% 14 5 (36%) 9 (64%) Location of disease 0.68 Lower third (62%) 25 (38%) Gastro-oesophageal junction (69%) 19 (31%) Other 8 5 (63%) 3 (37%) THORACIC The receiver operating characteristic area under the curve of the Ferguson pulmonary risk score system in this validation cohort was for predicting major pulmonary events (Fig. 4). Overall, this correlates to a discriminative ability of the score of 76% to predict these events. This indicates a moderate discriminative ability of this index. The Hosmer Lemeshow goodness-of-fit test indicated no difference between the expected and observed results (P = ). DISCUSSION Risk stratification is a valuable tool for surgeons in determining which patients are at increased risk for postoperative events. Further, in the new paradigm of health care delivery, with emphasis on value and quality of outcomes, surgeons must have the best and most up-to-date methods to accurately predict patient outcomes. The Goldman index for predicting postoperative
4 336 J.M. Reinersman et al. / European Journal of Cardio-Thoracic Surgery Figure 1: Distribution of risk scores for the study population. Figure 2: Incidence of pulmonary complications according to risk scores. Table 3: Incidence of pulmonary complications according to risk score quintiles Ferguson risk score category, no. Number of cases Major pulmonary complications (0%) (17%) (20%) (45%) (77%) P <0.001 cardiac events is perhaps the best known surgical risk stratification method, more recently updated into the revised cardiac risk index (RCRI) [4, 5]. The thoracic revised cardiac risk index is a further derivation of the RCRI, specialty specific, which predicts risk for major cardiovascular events after pulmonary resection [6]. These systems illustrate the applicability of global as well as specialty-specific risk scoring systems. Pulmonary complications continue to contribute to major morbidity and mortality after oesophagectomy. Ferguson et al. assessed their institution s database of over 30 years of oesophageal resections, and created a risk score to attempt to predict these complications. He further used his data to internally validate this model. We wished to assess this pulmonary risk score with an external cohort. Figure 3: Incidence of pulmonary complications according to risk score quintiles. Figure 4: Receiver operating characteristic curve for risk score and pulmonary complications (area under the curve = 0.762; 95% confidence interval: ; P <0.0001). Traditionally, pulmonary complications have been attributed to a variety of a factors, including advanced age, pulmonary dysfunction, performance status, use of thoracotomy, poor nutrition preoperatively, continued smoking and use of induction therapy [7 12]. The pulmonary risk scoring system evaluated in this study simplifies these down to four weighted variables: age, performance status, as defined by the Zubrod system, FEV1% and DLCO%. The incidence of pulmonary complications in our population was similar to the original score data set (35% compared with 38%). We also showed an association between pulmonary complications and prolonged length of stay and mortality. Overall, the morbidity rate was high, but is in line with current and historical large series of oesophageal resections [2, 13 16]. Our major pulmonary complication rate was slightly higher than other large series; however, we used a strict definition similar to that described by Ferguson et al. Many other studies only report pneumonia. Our cardiovascular morbidity was very low. Substantial disagreement exists whether neoadjuvant therapy increases the risk of postoperative morbidity and mortality.
5 J.M. Reinersman et al. / European Journal of Cardio-Thoracic Surgery 337 Multiple studies found that neoadjuvant therapy does increase the risk of morbidity postoperatively [7, 11, 17]. However, other prominent studies showed the opposite [8, 18 20]. Over 80% of patients in our series underwent neoadjuvant therapy with no difference in the rate of pulmonary complications. Ferguson made this conclusion from this series as well from his series [3]. The practice at our centre is to obtain pulmonary function tests 4 weeks after completion of neoadjuvant treatment, usually the day prior to surgery, allowing for a recovery period after chemotherapy and radiotherapy. Frailty often is described as a measure of physiological reserve, and has recently been used in attempts to predict postoperative morbidity and mortality [21 24]. Frailty is a factor increasingly recognized as contributing to adverse outcomes, and may enhance or supplant other risk scores in the future. For a predictive model to be clinically useful, ideally it is simple with few variables and rapid to interpret. The current frailty indices are unwieldy for use in busy day-to-day clinical practice. Ferguson et al. s model potentially could be a surrogate for these complex frailty indices. However, this composite score could be simplified into the Ferguson predictor since it includes an assessment of overall functional status (Zubrod/ECOG) and pulmonary function. One inherent bias in this study is that the data are from a single, high-volume centre. Secondly, this study is retrospective; however, the patients were collected prospectively in our department database. Further, the overall cohort from the time frame studied had a large number of missing pulmonary function test variables. This prevented imputation techniques to include more patients during this time frame. These missing tests also potentially may have skewed our results towards more debilitated patients being included, as presumably younger or patients in better condition may not have had preoperative pulmonary function tests. Examining the remaining cohort of 207 patients without pulmonary function tests during the time period, the overall pulmonary complication rate was 27% (56/207), with pneumonia in 24% (49/207) and isolated respiratory failure in 3% (7/207). Overall operative mortality in this cohort was 1% (3/207). Thus, as presupposed, the patients who did have pulmonary functions tests were a higher risk group based on the fact that the test was performed. Nevertheless, an examination of the combined cohort of 343 patients did not find that the choice to obtain pulmonary function tests themselves was an independent risk factor for major morbidity or mortality. In conclusion, we validated the Ferguson pulmonary risk score with an external independent series of oesophageal resections. Although the generalization of the present findings would benefit from a larger database validation, we believe that this validation supports the use of this score as a screening instrument during patient risk stratification prior to oesophagectomy. The Ferguson pulmonary risk scoring system is a reliable instrument to be used during the preoperative phase to differentiate patients who may be at higher risk for pulmonary complications after oesophagectomy. These data can assist in patient selection, patient education/ informed consent and guide postoperative management. SUPPLEMENTARY MATERIAL Supplementary Material is available at EJCTS online. Conflict of interest: none declared. REFERENCES [1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61: [2] Wright CD, Kucharczuk JC, O Brien SM, Grad JD, Allen MS. Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: A Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model. J Thorac Cardiovasc Surg 2009;137: [3] Ferguson MK, Celauro AD, Prachand V. Prediction of major pulmonary complications after esophagectomy. Ann Thorac Surg 2011;91: [4] Goldman L, Caldera DL, Nussbaum SR, Southwick FS, Krogstad D, Murray B et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med. 1977;297: [5] Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999;100: [6] Brunelli A, Varela G, Salati M, Jimenez MF, Pompili C, Novoa N et al. Recalibration of the revised cardiac risk index in lung resection candidates. Ann Thorac Surg 2010;90: [7] Avendaro CE, Flume PA, Silvestri GA, King LB, Reed CE. Pulmonary complications after esophagectomy. Ann Thorac Surg 2002;73: [8] Law S, Wong KH, Kwok KF, Chu KM, Wong J. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg 2004;240: [9] Atkins BZ, D Amico TA. Respiratory complications after esophagectomy. Thorac Surg Clin 2006;16: [10] Jiao WJ, Wang TY, Gong M, Pan H, Liu YB, Liu ZH. Pulmonary complications in patients with chronic obstructive pulmonary disease following transthoracic esophagectomy. World J Gastroenterol 2006;12: [11] Reynolds JV, Ravi N, Hollywood D, Kennedy MJ, Rowley S, Ryan A et al. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J Thorac Cardiovasc Surg 2006;132: [12] Grotenhuis BA, Wijnhoven BP, Grüne F, van Brommel J, Tilanus HW, van Lanschot JJ. Preoperative risk assessment and prevention of complications in patients with esophageal cancer. J Surg Oncol 2010;101: [13] Bailey SH, Bull DA, Harpole DH, Rentz JJ, Neumayer LA, Pappas TN et al. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg 2003;75: [14] Merkow RP, Bilimoria KY, McCarter MD, Phillips JD, DeCamp MM, Sherman KL et al. Short-term outcomes after esophagectomy at 164 American College of Surgeons National Surgical Quality Improvement Program hospitals. Arch Surg 2012;147: [15] Dhungel B, Diggs BS, Hunter JG, Sheppard BC, Vetto JT, Dolan JP. Patient and peri-operative predictors of mortality after esophagectomy: American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) J Gastrointest Surg 2010;14: [16] Takeuchi H, Miyata H, Gotoh M, Kitagawa Y, Baba H, Kimura W et al. A risk model for esophagectomy using data of 5,354 patients included in a Japanese nationwide web-based database. Ann Surg 2014;260: [17] Bosch DJ, Muijs CT, Mul VEM, Beukema JC, Hospers GAP, Burgerhof JGM et al. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients. Ann Surg Oncol 2014;21: [18] van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366: [19] Merritt RE, Whyte RI, D Arcy NT, Hoang CD, Shrager JB. Morbidity and mortality after esophagectomy following neoadjuvant chemoradiation. Ann Thorac Surg 2011;92: [20] Lin FC, Durkin AE, Ferguson MK. Induction therapy does not increase surgical morbidity after esophagectomy for cancer. Ann Thorac Surg 2004;78: [21] Mitnitski A, Mogilner A, Rockwood K. Accumulation of deficits as a proxy measure of aging. Sci World J 2001;1:323. [22] Velanovich V, Antoine H, Swartz A, Peters D, Rubinfeld I. Accumulating deficits model of frailty and postoperative mortality and morbidity: its application to a national database. J Surg Res 2013;183: [23] Karam J, Tsiouris A, Shepard A, Velanovich V, Rubinfeld I. Simplified frailty index to predict adverse outcomes and mortality in vascular surgery patients. Ann Vasc Surg 2013;27: [24] Hodari A, Hammoud ZT, Borgi JF, Tsiouris A, Rubinfeld IS. Assessment of morbidity and mortality after esophagectomy using a modified frailty index. Ann Thorac Surg 2013;96: THORACIC
6 338 J.M. Reinersman et al. / European Journal of Cardio-Thoracic Surgery APPENDIX. CONFERENCE DISCUSSION Scan to your mobile or go to to search for the presentation on the EACTS library Dr S. Rathinam (Leicester, UK): The risk complications of an oesophagectomy is a major factor and Dr Ferguson came up with a nice algorithm to identify that, and your group has validated it in a nice fashion. I have a few questions which might have a bearing on your results and outcomes. You have excluded a sizable proportion of your patients owing to lack of the full pulmonary function test. So what is your institution s preoperative work-up algorithm, and equally, how do these factors contribute to PPCs after oesophagectomy in terms of your mobilisation, physiotherapy contrast? So what is your postoperative algorithm? My second question is in terms of timing of your pulmonary lung function tests, in patients having induction therapy, do you repeat them before surgery, or do you go by the base value before the induction therapy? Dr Reinersman: Thank you. I will answer the second question first. Often, the patients have pulmonary function tests prior to neoadjuvant therapy, but we obtain repeat pulmonary function tests after neoadjuvant therapy prior to proceeding to resection. As for the first question, all patients have a history and physical and appropriate staging which includes EGD, EUS and a PET/CT. From this staging information, we consider whether these patients proceed directly to surgery, or if they have T3 or N1 positive tumours, then those patients will progress to concurrent neoadjuvant radiotherapy and chemotherapy. They come back four weeks afterwards, and are seen again, have a repeat history and physical exam, as well as a repeat PET/CT to look for distant metastases, and then we move forward with resection. Otherwise, as for who gets PFTs, I think over the recent past, now that we have realized the importance of PFTs, we have been starting to get them more often and in a majority of our patients; as opposed to previously, they were not available as often in the earlier patients two or three years ago. As for postoperative management, all of our patients are aggressively mobilized early. We work towards immediate extubation postoperatively so that we can have them up, walking around, with early pulmonary therapy, and pulmonary rehab. We have dedicated respiratory therapists on our ward, as well as a pulmonary care rehab centre that the patients are taken to on a daily basis to achieve these means. Dr D. Wood (Seattle, WA, USA): I have a couple of questions for you. One, back to the aspect of 207 patients not being included because they did not have PFTs, I am going to make a supposition that may be incorrect, but I am going to guess that those were better patients, patients that maybe looked really good, and therefore, did not have PFTs. So what we are seeing is a subset that you have analysed that is actually the patients with more co-morbidity. Do you think that is correct, and does that impact at all how to interpret this? Maybe 2 or 3 patients do not even get onto the scoring system, because they are in good shape. Dr Reinersman: Yes, we addressed this a bit in the manuscript. Due to the fact that our mortality, as well as other complications, was a bit higher than in our overall internal institutional database, these are likely sicker patients. The patients without PFTs upon initial assessment were likely healthier and were not deemed necessary to get pulmonary function tests ahead of time. Dr Wood: And my second question, I am presuming that a majority of your resections were Ivor-Lewis oesophagectomies? Dr Reinersman: Yes. Approximately 70% of them were Ivor-Lewis oesophagectomies. Dr Wood: Do you think this influences your new desire to get PFTs on everyone, if you are going to be doing a transhiatal oesophagectomy rather than a transthoracic oesophagectomy? Dr Reinersman: I think my inherent bias would be to say yes; however, in Dr Ferguson s original paper, he did show that there was no difference in risk in the patients who had a thoracotomy versus a transhiatal oesophagectomy. Dr A. Lerut (Leuven, Belgium): Following up on this aspect of access, were they all done by open surgery, or were they done by minimally invasive thoracoscopic and laparoscopic surgery? Because I guess that are interfering factors, and the other factor, which is not taken up in the Ferguson model. Or other surgical factors, like anastomotic leaks, where of course, you have a much higher chance for a pulmonary infection that therefore may interfere in this model. Were they all open surgeries? Dr Reinersman: The majority of them were open. Approximately 7% of the patients were done with a minimally invasive oesophagectomy, with usually a combination of a laparoscopic approach in the abdomen, and then some version of a robotic or thoracoscopic approach in the chest. Dr Lerut: And did you look at whether there was an influence from that minimally invasive access on your scoring model? Dr Reinersman: We did not specifically look at that in this dataset whether it made a difference. Dr Lerut: Any anastomotic leaks? Dr Reinersman: We did not assess whether that was associated, but the leak rate was approximately 10%. Dr G. Friedel (Stuttgart, Germany): A short question. I think 3 of your factors are not independent of a higher age. Maybe it has a higher ECOG, and maybe it has a decrease in FEV1? Dr Reinersman: I agree.
General introduction and outline of thesis
General introduction and outline of thesis General introduction and outline of thesis 11 GENERAL INTRODUCTION AND OUTLINE OF THESIS The incidence of esophageal cancer is increasing in the western world.
More informationIs surgical Apgar score an effective assessment tool for the prediction of postoperative complications in patients undergoing oesophagectomy?
Interactive CardioVascular and Thoracic Surgery 27 (2018) 686 691 doi:10.1093/icvts/ivy148 Advance Access publication 9 May 2018 BEST EVIDENCE TOPIC Cite this article as: Li S, Zhou K, Li P, Che G. Is
More informationAccepted Manuscript. Early stage (ct2n0) esophageal cancer: should induction therapy be a standard? Michael Lanuti, MD
Accepted Manuscript Early stage (ct2n0) esophageal cancer: should induction therapy be a standard? Michael Lanuti, MD PII: S0022-5223(18)30392-1 DOI: 10.1016/j.jtcvs.2018.02.029 Reference: YMTC 12608 To
More informationOverall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer
Original Article Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer Faisal A. Siddiqui 1, Katelyn M. Atkins 2, Brian S. Diggs 3, Charles R. Thomas Jr 1,
More informationFTS Oesophagectomy: minimal research to date 3,4
Fast Track Programme in patients undergoing Oesophagectomy: A Single Centre 5 year experience Sullivan J, McHugh S, Myers E, Broe P Department of Upper Gastrointestinal Surgery Beaumont Hospital Dublin,
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationLung Cancer in Octogenarians: Factors Affecting Morbidity and Mortality After Pulmonary Resection
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationThe Effect of Tidal Volume on Pulmonary Complications following Minimally Invasive Esophagectomy: A Randomized and Controlled Study
The Effect of Tidal Volume on Pulmonary Complications following Minimally Invasive Esophagectomy: A Randomized and Controlled Study Yaxing Shen, MD, Ming Zhong, MD, Lijie Tan, MD Zhongshan Hospital,Fudan
More informationMinimally Invasive Esophagectomy
Minimally Invasive Esophagectomy M A R K B E R R Y, M D A S S O C I AT E P R O F E S S O R D E PA R T M E N T OF C A R D I O T H O R A C I C S U R G E R Y S TA N F O R D U N I V E R S I T Y S E P T E M
More informationValidation of a Nomogram Predicting Complications After Esophagectomy for Cancer
Validation of a Nomogram Predicting Complications After Esophagectomy for Cancer Brechtje A. Grotenhuis, MD, Pieter van Hagen, MD, Johannes B. Reitsma, MD, PhD, Sjoerd M. Lagarde, MD, PhD, Bas P. L. Wijnhoven,
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationPrapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital
Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital Only 20-30% of patients with lung cancer are potential candidates for lung resection Poor lung function alone ruled
More informationDetermining the Optimal Surgical Approach to Esophageal Cancer
Determining the Optimal Surgical Approach to Esophageal Cancer Amit Bhargava, MD Attending Thoracic Surgeon Department of Cardiovascular and Thoracic Surgery Open Esophagectomy versus Minimally Invasive
More informationPostoperative Mortality in Lung Cancer Patients
Review Postoperative Mortality in Lung Cancer Patients Kanji Nagai, MD, Junji Yoshida, MD, and Mitsuyo Nishimura, MD Surgery for lung cancer frequently results in serious life-threatening complications,
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationAccuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a national cancer database analysis
Review Article Accuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a national cancer database analysis Ravi Shridhar 1, Jamie Huston 2, Kenneth L. Meredith 2 1 Department of Radiation
More informationMinimally Invasive Esophagectomy- Valuable. Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006
Minimally Invasive Esophagectomy- Valuable Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006 Overview Esophageal carcinoma What is minimally invasive esophagectomy (MIE)?
More informationSTS General Thoracic Surgery Database (GTSD) Update
STS General Thoracic Surgery Database (GTSD) Update Benjamin D. Kozower, MD, MPH Professor of Surgery Chair, STS GTSD Co-Director, Surgical Outcomes Research Center Washington University St. Louis, MO
More informationModeling major lung resection outcomes using classification trees and multiple imputation techniques
European Journal of Cardio-thoracic Surgery 34 (2008) 1085 1089 www.elsevier.com/locate/ejcts Modeling major lung resection outcomes using classification trees and multiple imputation techniques Mark K.
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationManagement of Esophageal Cancer: Evidence Based Review of Current Guidelines. Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center
Management of Esophageal Cancer: Evidence Based Review of Current Guidelines Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center Case Presentation 68 y/o male PMH: NIDDM, HTN, hyperlipidemia, CAD s/p stents,
More informationThe Society of Thoracic Surgeons General Thoracic Surgery Database: Establishing Generalizability to National Lung Cancer Resection Outcomes
The Society of Thoracic Surgeons General Thoracic Surgery Database: Establishing Generalizability to National Lung Cancer Resection Outcomes Damien J. LaPar, MD, MS, Castigliano M. Bhamidipati, DO, MS,
More informationControversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
More informationMINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER: where do we stand?
MINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER: where do we stand? Ph Nafteux, MD Copenhagen, Nov 3rd 2011 Department of Thoracic Surgery, University Hospitals Leuven, Belgium W. Coosemans, H. Decaluwé, Ph.
More informationMinimally Invasive Esophagectomy: OVERRATED!!! Sagar Damle UCHSC December 11, 2006
Minimally Invasive Esophagectomy: OVERRATED!!! Sagar Damle UCHSC December 11, 2006 Esophageal Cancer - Est. 15,000 cases in 2006 - Est. 14,000 deaths - Overall 5-year survival: 15.6% - 33.6 % for local
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationAs the proportion of the elderly in the
CANCER When the cancer patient is elderly, how do you weigh the risks of surgery? Marguerite Palisoul, MD Dr. Palisoul is Fellow in the Department of Obstetrics and Gynecology, Division of Gynecologic
More informationThe CROSS road in neoadjuvant therapy for esophageal cancer: long-term results of CROSS trial
Editorial The CROSS road in neoadjuvant therapy for esophageal cancer: long-term results of CROSS trial Ian Wong, Simon Law Division of Esophageal and Upper Gastrointestinal Surgery, Department of Surgery,
More informationSurgical strategies in esophageal cancer
Gastro-Conference Berlin 2005 October 1-2, 2005 Surgical strategies in esophageal cancer J. Rüdiger Siewert Department of Surgery, Klinikum rechts der Isar Technische Universität München Esophageal Cancer
More informationEarly extubation after transthoracic oesophagectomy
Key words: Analgesia, epidural; Esophagectomy; Mortality; Postoperative complications; Ventilation "#$ " "# FHY Yap JYW Lau GM Joynt PT Chui ACW Chan SSC Chung Hong Kong Med J 2003;9:98-102 Prince of Wales
More informationCarcinoma of the esophagus continues to carry a
Pulmonary Complications After Esophagectomy Christopher E. Avendano, MD, Patrick A. Flume, MD, Gerard A. Silvestri, MD, Lydia B. King, MPH, and Carolyn E. Reed, MD Departments of Medicine, Biometry and
More informationIs laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass?
Is laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass? A comparison of 30-day complications using the MBSAQIP data registry Sandhya B. Kumar MD, Barbara C. Hamilton MD, Soren Jonzzon,
More informationOutcomes After Esophagectomy: A Ten-Year Prospective Cohort
J. MAXWELL CHAMBERLAIN MEMORIAL PAPER Outcomes After Esophagectomy: A Ten-Year Prospective Cohort Stephen H. Bailey, MD, David A. Bull, MD, David H. Harpole, MD, Jeffrey J. Rentz, MD, Leigh A. Neumayer,
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationAliu Sanni MD SUNY Downstate Medical Center August 16, 2012
Aliu Sanni MD SUNY Downstate Medical Center August 16, 2012 Case Presentation 60yr old AAF with PMH of CAD s/p PCI 1983, CVA, GERD, HTN presented with retrosternal chest pain on 06/12 Associated dysphagia
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationDifferent Diffusing Capacity of the Lung for Carbon Monoxide as Predictors of Respiratory Morbidity
Different Diffusing Capacity of the Lung for Carbon Monoxide as Predictors of Respiratory Morbidity Robert J. Cerfolio, MD, and Ayesha S. Bryant, MSPH, MD Department of Surgery, Division of Cardiothoracic
More informationFEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2010 FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery Nicholas L Mills, David A McAllister, Sarah Wild, John D MacLay,
More informationDATA REPORT. August 2014
AUDIT DATA REPORT August 2014 Prepared for the Australian and New Zealand Gastric and Oesophageal Surgical Association by the Royal Australasian College of Surgeons 199 Ward St, North Adelaide, SA 5006
More informationPreoperative Workup for Pulmonary Resection. Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016
Preoperative Workup for Pulmonary Resection Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016 Patient Presentation 50 yo male with 70 pack year smoking history Large R hilar lung
More informationUCLA General Surgery Residency Program Rotation Educational Policy Goals and Objectives
UPDATED: July 2009 ROTATION: THORACIC SURGERY UCLA General Surgery Residency Program ROTATION DIRECTOR: Mary Maish, M.D. CHIEF OF CARDIAC SURGERY: Robert Cameron, M.D. SITES: UCLA Medical Center - Westwood
More informationT2N0 Esophageal Cancer: Does it Exist? Should we give Preop Therapy?
T2N0 Esophageal Cancer: Does it Exist? Should we give Preop Therapy? Traves D. Crabtree Associate Professor of Surgery Washington University School of Medicine I am a consultant for Ethicon Endo-Surgery
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationMOLECULAR AND CLINICAL ONCOLOGY 3: , 2015
MOLECULAR AND CLINICAL ONCOLOGY 3: 133-138, 2015 Assessment of health related quality of life of patients with esophageal squamous cell carcinoma following esophagectomy using EORTC quality of life questionnaires
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationRobotic lobectomy has the greatest benefit in patients with marginal pulmonary function
Kneuertz et al. Journal of Cardiothoracic Surgery (2018) 13:56 https://doi.org/10.1186/s13019-018-0748-z RESEARCH ARTICLE Open Access Robotic lobectomy has the greatest benefit in patients with marginal
More informationRisk factors for the development of respiratory complications and anastomotic leakage after esophagectomy
Risk factors for the development of respiratory complications and anastomotic leakage after esophagectomy MED-3950 5-årsuppgaven- Profesjonsstudiet I medisin ved Universitetet I Tromsø Katarina Margareta
More informationPreoperative Biliary Drainage Among Patients With Resectable Hepatobiliary Malignancy: Does Technique Matter?
Preoperative Biliary Drainage Among Patients With Resectable Hepatobiliary Malignancy: Does Technique Matter? Q. Lina Hu, MD; Jason B. Liu, MD, MS; Ryan J. Ellis, MD, MS; Jessica Y. Liu, MD, MS; Anthony
More informationThe Impact of Body Mass Index on Esophageal Cancer
Obesity does not appear to affect the morbidity of treatments for esophageal cancer. Samuel Bak. BK1464 Added Perspective I. Oil on canvas, 12ʺ 16ʺ. The Impact of Body Mass Index on Esophageal Cancer Joyce
More informationJejunostomy after oesophagectomy, how and why I do it
Jejunostomy after oesophagectomy, how and why I do it Graeme Couper. Consultant Oesophago-gastric Surgeon, The Royal Infirmary of Edinburgh BAPEN Conference 2010 2nd & 3rd November Harrogate International
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationIndex. Note: Page numbers of article titles are in boldface type
Index Note: Page numbers of article titles are in boldface type A Acute coronary syndrome, perioperative oxygen in, 599 600 Acute lung injury (ALI). See Lung injury and Acute respiratory distress syndrome.
More informationANTICANCER RESEARCH 34: (2014)
The Impact of Combined Thoracoscopic and Laparoscopic Surgery on Pulmonary Complications After Radical Esophagectomy in Patients With Resectable Esophageal Cancer NAOSHI KUBO 1, MASAICHI OHIRA 1, YOSHITO
More informationORIGINAL ARTICLE. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 49 (2016) 1054 1058 doi:10.1093/ejcts/ezv378 Advance Access publication 24 November 2015 ORIGINAL ARTICLE Cite this article as: Begum SSS, Papagiannopoulos K,
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients
More informationSurgical resection alone remains a worldwide standard for
Original Article Influence of Preoperative Radiation Field on Postoperative Leak Rates in Esophageal Cancer Patients after Trimodality Therapy Aditya Juloori, BS,* Susan L. Tucker, PhD, Ritsuko Komaki,
More informationPOSTOPERATIVE COMPLICATIONS OF TRANSTHORACIC ESOPHAGECTOMY FOR ESOPHAGEAL CARCINOMA
International International Multidisciplinary Multidisciplinary e Journal/ e-journal Dr. A. Razaque Shaikh, Dr. Khenpal Das, Dr Shahida Khatoon ISSN 2277. (133-140) - 4262 POSTOPERATIVE COMPLICATIONS OF
More informationRESEARCH ARTICLE. Noriatsu Tatematsu 1 *, Moonhwa Park 1, Eiji Tanaka 2, Yoshiharu Sakai 2, Tadao Tsuboyama 1. Abstract.
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.1.47 RESEARCH ARTICLE Association between Physical Activity and Postoperative Complications after Esophagectomy for Cancer: A Prospective Observational Study
More informationOutcome of Esophagectomy for Cancer in Elderly Patients
Outcome of Esophagectomy for Cancer in Elderly Patients Tanja M. Cijs, MD, Cees Verhoef, MD, PhD, Ewout W. Steyerberg, PhD, Linetta B. Koppert, MD, PhD, T. C. Khe Tran, MD, Bas P. L. Wijnhoven, MD, PhD,
More informationOutcomes associated with robotic approach to pancreatic resections
Short Communication (Management of Foregut Malignancies and Hepatobiliary Tract and Pancreas Malignancies) Outcomes associated with robotic approach to pancreatic resections Caitlin Takahashi 1, Ravi Shridhar
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationAccepted Manuscript. Current State of the Art for the Surgical Management of empyema thoracis. K. Robert Shen, M.D.
Accepted Manuscript Current State of the Art for the Surgical Management of empyema thoracis K. Robert Shen, M.D. PII: S0022-5223(18)32919-2 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.006 Reference:
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationAssociation of Age and Survival in Patients With Gastroesophageal Cancer Undergoing Surgery With or Without Preoperative Therapy
Association of Age and Survival in Patients With Gastroesophageal Cancer Undergoing Surgery With or Without Preoperative Therapy Fadi Braiteh, MD 1 ; Arlene M. Correa, PhD 2 ; Wayne L. Hofstetter, MD 2
More informationAlthough surgical resection is the best treatment for localized. Predictors of Postoperative Quality of Life after Surgery for Lung Cancer
ORIGINAL ARTICLE Predictors of Postoperative Quality of Life after Surgery for Lung Cancer Axel Möller* and Ulrik Sartipy, MD, PhD Introduction: The aim was to analyze the association between selected
More informationNational Oesophago-Gastric Cancer Audit New Patient Registration sheet Patients with Oesophageal High Grade Glandular Dysplasia
National Oesophago-Gastric Cancer Audit New Patient Registration sheet Patients with Oesophageal High Grade Glandular Dysplasia Patient Details Surname: NHS number: Forename: Postcode: Sex: Male Female
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationMouth & Body Current information about medical-dental cooperative clinical practices for cancer patients
Mouth & Body body. Topics A healthy mouth leads to a sound VOL.2 Current information about medical-dental cooperative clinical practices for cancer patients Yasuhiro Tsubosa, MD, PhD Chief of Division
More informationForm 1: Demographics
Form 1: Demographics Case Number: *LMRN: *DOB: / / *Gender: Male Female *Race: White Native Hawaiian/Other Pacific Islander Black or African American Asian American Indian or Alaska Native Unknown *Hispanic
More informationImpact of Tidal Volume on Complications after Thoracic Surgery
Management of One-lung Ventilation Impact of Tidal Volume on Complications after Thoracic Surgery ABSTRACT Background: The use of lung-protective ventilation (LPV) strategies may minimize iatrogenic lung
More informationAssociation of a Modified Frailty Index with Postoperative Outcomes after Ankle Fractures in Patients Aged 55 and Older
Association of a Modified Frailty Index with Postoperative Outcomes after Ankle Fractures in Patients Aged 55 and Older Rishin J. Kadakia MD; Cathy Vu MD; Andrew Pao MD; Shay Tenenbaum MD, Jason T. Bariteau
More informationParenchymal air leak is a frequent complication after. Pleural Tent After Upper Lobectomy: A Randomized Study of Efficacy and Duration of Effect
Pleural After Upper Lobectomy: A Randomized Study of Efficacy and Duration of Effect Alessandro Brunelli, MD, Majed Al Refai, MD, Marco Monteverde, MD, Alessandro Borri, MD, Michele Salati, MD, Armando
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationNewly Diagnosed Cases Cancer Related Death NCI 2006 Data
Multi-Disciplinary Management of Esophageal Cancer: Surgical and Medical Steps Forward Alarming Thoracic Twin Towers 200000 150000 UCSF UCD Thoracic Oncology Conference November 21, 2009 100000 50000 0
More informationTranshiatal Esophagectomy: Lower Mortality, Diminished Morbidity, Equal Effectiveness
Transhiatal Esophagectomy: Lower Mortality, Diminished Morbidity, Equal Effectiveness Sunil Malhotra, M.D. Department of Surgery University of Colorado Resident Debate April 30, 2007 Esophageal Cancer
More informationThe Learning Curve for Minimally Invasive Esophagectomy
The Learning Curve for Minimally Invasive Esophagectomy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J Swanson, M.D. Professor of Surgery Harvard
More informationDemographics. MBSAQIP Case Number: *ACS NSQIP Case Number: *LMRN: *DOB: / / *Gender: Male Female
Demographics MBSAQIP Case Number: *IDN: *ACS NSQIP Case Number: Name: *LMRN: *DOB: / / *Gender: Male Female *Race: White Black or African American American Indian or Alaska Native Native Hawaiian/Other
More informationFariba Rezaeetalab Associate Professor,Pulmonologist
Fariba Rezaeetalab Associate Professor,Pulmonologist rezaitalabf@mums.ac.ir Patient related risk factors Procedure related risk factors Preoperative risk assessment Risk reduction strategies Age Obesity
More informationPulmonary Function Tests Do Not Predict Pulmonary Complications After Thoracoscopic Lobectomy
Pulmonary Function Tests Do Not Predict Pulmonary Complications After Thoracoscopic Lobectomy Mark F. Berry, MD, Nestor R. Villamizar-Ortiz, MD, Betty C. Tong, MD, William R. Burfeind, Jr, MD, David H.
More informationPredicting Short Term Morbidity following Revision Hip and Knee Arthroplasty
Predicting Short Term Morbidity following Revision Hip and Knee Arthroplasty A Review of ACS-NSQIP 2006-2012 Arjun Sebastian, M.D., Stephanie Polites, M.D., Kristine Thomsen, B.S., Elizabeth Habermann,
More informationEarly and locally advanced non-small-cell lung cancer (NSCLC)
Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationPubmed citation for the paper: Acta Oncol Feb 28. [Epub ahead of print]
This is an author produced version of a paper published in Acta Oncologica. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination. Pubmed citation
More informationImpact of co-morbidity on mortality after oesophageal cancer surgery
Original article Impact of co-morbidity on mortality after oesophageal cancer surgery L. Backemar 1, P. Lagergren 1,A.Johar 1 and J. Lagergren 2,3 1 Surgical Care Science and 2 Upper Gastrointestinal Surgery,
More informationChina 3 School of Pharmacy, Jiangsu University, Zhenjiang, Jiangsu, , People s Republic of China. *Corresponding authors: Godwin Botwe
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 6 Ver. 2 (June. 2018), PP 63-68 www.iosrjournals.org The Relationship among Demographic Factors,
More informationEfficacy of Intraoperative, Single-Bolus Corticosteroid Dose to Prevent Postoperative Respiratory Complication after Transhiatal Esophagectomy
Efficacy of Intraoperative, Single-Bolus Corticosteroid Dose to Prevent Postoperative Respiratory Complication after Transhiatal Esophagectomy Reza Afghani 1, Reza Bagheri 2 *, Seyed Ziaollah Haghi 2,
More informationDelay in Diagnostic Workup and Treatment of Esophageal Cancer
J Gastrointest Surg (2010) 14:476 483 DOI 10.1007/s11605-009-1109-y ORIGINAL ARTICLE Delay in Diagnostic Workup and Treatment of Esophageal Cancer Brechtje A. Grotenhuis & Pieter van Hagen & Bas P. L.
More informationOptimal technique for the removal of chest tubes after pulmonary resection
Optimal technique for the removal of chest tubes after pulmonary resection Robert James Cerfolio, MD, FACS, FCCP, a,b Ayesha S. Bryant, MD, MSPH, c Loki Skylizard, MD, d and Douglas J. Minnich, MD, FACS
More informationThe STS Database is the Best Measure of Quality: CON
The STS Database is the Best Measure of Quality: CON Inderpal (Netu) S. Sarkaria, MD, FACS Vice Chairman, Clinical Affairs Director, Robotic Thoracic Surgery Co-Director, Esophageal and Lung Surgery Institute
More informationComparison of three mathematical prediction models in patients with a solitary pulmonary nodule
Original Article Comparison of three mathematical prediction models in patients with a solitary pulmonary nodule Xuan Zhang*, Hong-Hong Yan, Jun-Tao Lin, Ze-Hua Wu, Jia Liu, Xu-Wei Cao, Xue-Ning Yang From
More informationPre-operative Evaluations. Objectives. General Considerations. FP Consultation Considerations. CV Credits 7/24/2017. Brian Bachelder, MD Akron, Ohio
Pre-operative Evaluations Brian Bachelder, MD Akron, Ohio Objectives Discuss the perioperative cardiopulmonary evaluation and management of patients undergoing non-cardiac surgery Objectively estimate
More informationPart II. A randomized trial
77 Part II A randomized trial 78 79 Chapter 5 Preliminary experience of minimally invasive esophagectomy for cancer. Maas KW Biere SSAY Gisbertz SS van der Peet DL M.A. Cuesta Submitted 80 Chapter 5 ABSTRACT
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationPOSTGRADUATE INSTITUTE OF MEDICINE UNIVERSITY OF COLOMBO
POSTGRADUATE INSTITUTE OF MEDICINE UNIVERSITY OF COLOMBO MD (ANAESTHESIOLOGY) FINAL EXAMINATION AUGUST 2013 Date : 2 nd August 2013 Time : 1.00 p.m. 4.00 p.m. Answer any three questions. Answer each question
More informationIntroduction. Roxanne L. Massoumi 1 Colleen M. Trevino
World J Surg (2017) 41:935 939 DOI 10.1007/s00268-016-3816-3 ORIGINAL SCIENTIFIC REPORT Postoperative Complications of Laparoscopic Cholecystectomy for Acute Cholecystitis: A Comparison to the ACS-NSQIP
More informationLymph node metastasis is one of the most important prognostic
ORIGINAL ARTICLE Comparison of Survival and Recurrence Pattern Between Two-Field and Three-Field Lymph Node Dissections for Upper Thoracic Esophageal Squamous Cell Carcinoma Young Mog Shim, MD, Hong Kwan
More informationIncidence and management of chylothorax after esophagectomy
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Incidence and management of chylothorax after esophagectomy Longsheng Miao 1,2, Yawei Zhang 1,2, Hong Hu 1,2, Longfei Ma 1,2, Yihua Shun 1,2, Jiaqing Xiang
More information